Objective The clinical manifestation, curative effect, overall survival (OS) and progressionfree survival (PFS) of patients with IgA type multiple myeloma (MM) were analyzed retrospectively. Methods The clinical data of 33 patients with IgA type MM hospitalized in the hematology department of the Second Affiliated Hospital of Xi'an Jiaotong University from January 2009 to October 2018 were collected to analyze the clinical characteristics, the efficacy and longterm survival of different treatment plans. Results The most common clinical manifestations of IgA MM were bone destruction, anemia and infection. There was abnormal cytogenetics in 21 patients. The proportion of CR or VGPR obtained by borotezomi therapy was significantly higher than that of traditional chemotherapy group. The level of MRD was determined in 24 patients when the first CR was obtained. 667% patients were with negative MRD. The recurrence rate of MRD negative group was significantly lower than that of MRD positive group. The median followup time of 33 patients was 33 months(5127). The overall survival rate was 813%(26/32). The 1year and 2year PFS rate were 72% and 37%. The median survival time was not reached. The median PFS time is 22 months. The median PFS time of MRD negative patients was significantly longer than that of MRD positive group.Conclusion Bone lesions, anemia and cytogenetics of poor prognosis are common in IgA type MM. MRD positive is its adverse prognostic factor. The borotezomi can improve the treatment efficacy and the IgA type MM prognosis.